Notable
SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
Recruitment opened
Shenyang Sunshine Pharmaceutical Co., LTD.Phase 2 NCT07757230 Registry history of NCT07757230 on ClinicalTrials.gov (opens the registry)